$RCMT

Saks Michael sold $411K of RCMT

Saks Michael (Division President, HC Srvs.) sold 10,000 shares of RCM TECHNOLOGIES, INC. (RCMT) at an average of $41.07 ($40.78–$41.24, $0.41M total) across 2 trades on 2026-08-18.

Original reporting
SEC EDGAR · Saks Michael
Published Aug 20, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RCMT
Bearish
medium confidence
Mentioned
$RCMT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCMTBearishLow
01

Why it matters

A modest insider sell may prompt short‑term traders to watch for price weakness, but the effect is likely muted.

02

Market read

Primary disclosure of a small insider sale; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or earnings that may offset the sale impact.

Relevance 4/10Novelty 4/10Timing: filed today (2026‑08‑20)

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$RCMTBearishMedium confidence
Context

Division President Michael Saks sold 10,000 shares for $410,681, reducing his stake to 89,307 shares.

Expected impact

minor short-term dip, likely <1% move

Evidence & confidence

Sale size is modest relative to market cap and insider role; no pre‑arranged plan, so impact is limited.

Market effects

None significant; the sale is company‑specific.

No broader regional effect.

Limited to RCMT investors.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • RCMT Technologies, Inc.

    Issuer of the Form 4 filing.

  • Michael Saks

    Division President, HC Srvs., reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).